Meltzer EO, et al. - Herein, researchers reviewed the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with varying degrees of asthma severity. They also looked at the role of the parasympathetic nervous system in the pathophysiology of asthma, the development of tiotropium for respiratory disease, and the value of the Respimat inhaler. They found that treatment with once-daily tiotropium Respimat 2.5 micrograms was effective in this patient population and was as safe as placebo. Further positive attributes of this treatment included once-daily dosing, administration by inhalation, and delivery in the easy-to-use and consistent-dosing Respimat device.